DGIdb - RITUXIMAB Drug Record

RITUXIMAB chembl:CHEMBL1201576 ApprovedAntineoplasticImmunotherapy

Alternate Names:

HS006
IDEC-102
SAIT-101
MABTHERA RITUXAN
R-105 IDEC-102
ABP-798
CT-P10
MABTHERA
RITUXAN
RG-105
HS-006
RHCACD20MA
SAIT101
HS-006 (RITUXIMAB BIOSIMILAR)
RITUXIMAB
IDEC-C2B8
ANTICD20
IG GAMMA-1 CHAIN C REGION
drugbank:00073
chembl:CHEMBL1201576
rxcui:121191
chemidplus:174722-31-7

Drug Info:

FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
Drug Class	antineoplastic agents
Year of Approval	1997
FDA Approval	Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis
Drug Class	Therapeutic Antibodies

(5 More Sources)

Publications:

Jaglowski et al., 2010, Rituximab in chronic lymphocytic leukemia., Semin. Hematol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
van Meerten et al., 2010, CD20-targeted therapy: the next generation of antibodies., Semin. Hematol.
McLaughlin P et al., 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program., J Clin Oncol
Epeldegui M et al., 2016, Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)., Clin Cancer Res
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
Ghetie et al., Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts., J. Immunother.
Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
Márquez A et al., 2013, IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients., Mol Biol Rep
Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol
Hatjiharissi et al., 2007, Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy., Clin Lymphoma Myeloma
Kim et al., 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood
Kim SH et al., 2015, Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab., JAMA Neurol
Quartuccio L et al., 2014, The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study., Ann Rheum Dis
Nishio M et al., 2009, FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation., Eur J Haematol
Weng WK et al., 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma., J Clin Oncol
Niwa et al., 2004, Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism., Clin. Cancer Res.
Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
Alas et al., 2002, Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma., Clin. Cancer Res.
Morimoto et al., 2005, Use of rituximab to treat refractory Diamond-Blackfan anemia., Eur. J. Haematol.

RITUXIMAB CXCL13

Interaction Score: 8.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26384320

Sources:
PharmGKB
RITUXIMAB MS4A1

Interaction Score: 2.7

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Trial Name Rituxan

PMIDs:
20350663 11752352 20350667 9704735

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA
RITUXIMAB FCGR2A

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30457672 17324336 16609067

Sources:
PharmGKB
RITUXIMAB LOH19CR1

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15813920

Sources:
NCI
RITUXIMAB FCGR3A

Interaction Score: 1.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30457672 26167726 23505228 19018870 16609067 12975461 17324336 15448014

Sources:
PharmGKB
RITUXIMAB GSTA1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 19448608

Sources:
PharmGKB
RITUXIMAB CXCL12

Interaction Score: 1.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27173875

Sources:
PharmGKB
RITUXIMAB IL10

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26384320

Sources:
PharmGKB
RITUXIMAB XIAP

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11895917

Sources:
NCI
RITUXIMAB IL6

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26384320

Sources:
PharmGKB
RITUXIMAB IL2

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23645042

Sources:
PharmGKB
RITUXIMAB TGFB1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22129793

Sources:
PharmGKB
RITUXIMAB ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16971809 25637052

Sources:
NCI PharmGKB
RITUXIMAB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11895917

Sources:
NCI

TEND: RITUXIMAB
- Version: 01-August-2011
Alternate Names:

RITUXIMAB Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class antineoplastic agents

Publications:
MyCancerGenome: RITUXIMAB
- Version: 20-Jun-2017
Alternate Names:

IDEC-102 Development Name

IDEC-C2B8 Development Name

RITUXIMAB Generic Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis

Publications:
TdgClinicalTrial: RITUXIMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:

NCI: RITUXIMAB

Version: 14-September-2017

Alternate Names:

C1702 NCI drug code

Drug Info:

Publications:

Alas et al., 2002, Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma., Clin. Cancer Res.

Ghetie et al., Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts., J. Immunother.

Morimoto et al., 2005, Use of rituximab to treat refractory Diamond-Blackfan anemia., Eur. J. Haematol.

PharmGKB: rituximab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Epeldegui M et al., 2016, Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)., Clin Cancer Res

Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

TTD: Rituximab
- Version: 2020.06.01
Alternate Names:

D09EXD TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201576
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201576
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Rituximab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	B-lymphocyte antigen CD20 inhibitor
Direct Interaction	yes
Trial Name	Rituxan

IDEC-102	Development Name
IDEC-C2B8	Development Name
RITUXIMAB	Generic Name

antibody (inhibitory)
inhibitor (inhibitory)

RITUXIMAB Drug Record

RITUXIMAB chembl:CHEMBL1201576 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26384320

Sources: PharmGKB

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor Direct Interaction yes Trial Name Rituxan

PMIDs: 20350663 11752352 20350667 9704735

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30457672 17324336 16609067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15813920

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30457672 26167726 23505228 19018870 16609067 12975461 17324336 15448014

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 19448608

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27173875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26384320

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11895917

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26384320

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23645042

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22129793

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16971809 25637052

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11895917

Sources: NCI

TEND: RITUXIMAB

Alternate Names: RITUXIMAB Primary Drug Name

Drug Info: Year of Approval 1997 Drug Class antineoplastic agents

Publications:

MyCancerGenome: RITUXIMAB

Alternate Names: IDEC-102 Development Name IDEC-C2B8 Development Name RITUXIMAB Generic Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis

Publications:

TdgClinicalTrial: RITUXIMAB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval approved

Publications:

NCI: RITUXIMAB

Alternate Names: C1702 NCI drug code

Drug Info:

PharmGKB: rituximab

Alternate Names:

Drug Info:

TTD: Rituximab

Interaction Types & Directionality:

n/a

PMIDs:
26384320

Sources:
PharmGKB

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Trial Name Rituxan

PMIDs:
20350663 11752352 20350667 9704735

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA

Interaction Types & Directionality:

n/a

PMIDs:
30457672 17324336 16609067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15813920

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
30457672 26167726 23505228 19018870 16609067 12975461 17324336 15448014

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29938344 19448608

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27173875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26384320

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11895917

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26384320

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23645042

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22129793

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16971809 25637052

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11895917

Sources:
NCI

Alternate Names:

RITUXIMAB Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class antineoplastic agents

Alternate Names:

IDEC-102 Development Name

IDEC-C2B8 Development Name

RITUXIMAB Generic Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis, Granulomatosis with polyangiitis

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

C1702 NCI drug code

Alternate Names:

D09EXD TTD Drug ID